Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.

Eiichi OgawaMakoto NakamutaToshimasa KoyanagiAritsune OohoNorihiro FurusyoEiji KajiwaraKazufumi DohmenAkira KawanoTakeaki SatohKazuhiro TakahashiKoichi AzumaNobuyuki YamashitaNaoki YamashitaRie SugimotoHiromasa AmagaseMasami KuniyoshiYasunori IchikiChie MoritaMasaki KatoShinji ShimodaHideyuki NomuraJun Hayashinull null

Published in: Hepatology international (2022)

Based on this longitudinal data analysis up to 96 weeks, sequential NA therapy with a switch to TAF is a good option to achieve high viral suppression and renal safety.

Keyphrases

data analysis
hepatitis b virus
cross sectional
sars cov
randomized controlled trial
stem cells
liver failure
gestational age
combination therapy
preterm birth